• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
Citation: XING Xuyang, WANG Xiaochun, HE Wei. Advances in research on tumor immunotherapy and its drug development[J]. Journal of China Pharmaceutical University, 2021, 52(1): 10-19. DOI: 10.11665/j.issn.1000-5048.20210102
shu

Advances in research on tumor immunotherapy and its drug development

  • Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No.81872823) and the Double First-Class Project of China Pharmaceutical University (No.CPU2018PZQ13)
More Information
  • Received Date: June 24, 2020
  • Revised Date: July 09, 2020
    Graphical Abstract
    • Abstract
  • The progress of molecular biology and tumor biology has greatly changed the mode of cancer treatment. A large number of scientific studies have revealed the mechanism of tumor immune evasion, and a variety of new types of tumor immunotherapy have emerged, which has become another effective treatment of cancer after surgery, radiotherapy, chemotherapy and targeted therapy. This paper introduces the mechanism of tumor cell immune evasion, and focuses on the design principle, biological drugs and the latest research progress of immunotherapy, such as cytokine immunotherapies, therapeutic monoclonal antibody immunotherapy, PD-1/PD-L1 therapy, CAR-T therapy, tumor vaccine, oncolytic virus and so on. At the same time, the advantages and disadvantages of various immunotherapies are compared to provide reference for drug research and development in tumor immunotherapy.
    • FullText(HTML)
    • References (56)
  • [1]
    . Cell， 2019， 176（3）： 677.
    [2]
    Pham T， Roth S， Kong J， et al. An update on immunotherapy for solid tumors： a review［J］. Ann Surg Oncol， 2018， 25（11）： 3404-3412.
    [3]
    Chang CH， Qiu J， O''Sullivan D， et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression［J］. Cell， 2015， 162（6）： 1229-1241.
    [4]
    Klener P， Jr.， Otahal P， Lateckova L， et al. Immunotherapy approaches in cancer treatment［J］. Curr Pharm Biotechnol， 2015， 16（9）： 771-781.
    [5]
    Liu YH， Zang XY， Wang JC， et al. Diagnosis and management of immune related adverse events （irAEs） in cancer immunotherapy［J］. Biomedecine Pharmacother， 2019， 120： 109437.
    [6]
    Weiner GJ. Building better monoclonal antibody-based therapeutics［J］. Nat Rev Cancer， 2015， 15（6）： 361-370.
    [7]
    Sedykh SE， Prinz VV， Buneva VN， et al. Bispecific antibodies： design， therapy， perspectives［J］. Drug Des Devel Ther， 2018， 12： 195-208.
    [8]
    Labrijn AF， Janmaat ML， Reichert JM， et al. Bispecific antibodies： a mechanistic review of the pipeline［J］. Nat Rev Drug Discov， 2019， 18（8）： 585-608.
    [9]
    Lindau D， Gielen P， Kroesen M， et al. The immunosuppressive tumour network： myeloid-derived suppressor cells， regulatory T cells and natural killer T cells［J］. Immunology， 2013， 138（2）： 105-115.
    [10]
    Qin H， Lerman B， Sakamaki I， et al. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice［J］. Nat Med， 2014， 20（6）： 676-681.
    [11]
    Liu C， Workman CJ， Vignali DA. Targeting regulatory T cells in tumors［J］. Febs J， 2016， 283（14）： 2731-2748.
    [12]
    de Coa?a YP， Wolodarski M， Poschke I， et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma［J］. Oncotarget， 2017， 8（13）： 21539-21553.
    [13]
    Buchbinder EI， Desai A. CTLA-4 and PD-1 pathways： similarities， differences， and implications of their inhibition［J］. Am J Clin Oncol， 2016， 39（1）： 98-106.
    [14]
    Abdin SM， Zaher DM， Arafa EA， et al. Tackling cancer resistance by immunotherapy： updated clinical impact and safety of PD-1/PD-L1 inhibitors［J］. Cancers （Basel）， 2018， 10（2）： E32.
    [15]
    Iwai Y， Ishida M， Tanaka Y， et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade［J］. Proc Natl Acad Sci USA， 2002， 99（19）： 12293-12297.
    [16]
    Rowshanravan B， Halliday N， Sansom DM. CTLA-4： a moving target in immunotherapy［J］. Blood， 2018， 131（1）： 58-67.
    [17]
    Syn NL， Teng MWL， Mok TSK， et al. De-novo and acquired resistance to immune checkpoint targeting［J］. Lancet Oncol， 2017， 18（12）： e731-e741.
    [18]
    Dong HD， Strome SE， Salomao DR， et al. Tumor-associated B7-H1 promotes T-cell apoptosis： a potential mechanism of immune evasion［J］. Nat Med， 2002， 8（8）： 793-800.
    [19]
    Sul J，Blumenthal GM，Jiang XP， et al. FDA approval summary： pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1［J］. Oncologist， 2016， 21（5）： 643-650.
    [20]
    Ning YM， Suzman D， Maher VE， et al. FDA approval summary： atezolizumab for the treatment of patients with progressive advanced urothelial carcinoma after platinum-containing chemotherapy［J］. Oncologist， 2017， 22（6）： 743-749.
    [21]
    Michot JM， Bigenwald C， Champiat S， et al. Immune-related adverse events with immune checkpoint blockade： a comprehensive review［J］. Eur J Cancer， 2016， 54： 139-148.
    [22]
    Maude SL， Laetsch TW， Buechner J， et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia［J］. N Engl J Med， 2018， 378（5）： 439-448.
    [23]
    Locke FL， Ghobadi A， Jacobson CA， et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma （ZUMA-1）： a single-arm， multicentre， phase 1-2 trial［J］. Lancet Oncol， 2019， 20（1）： 31-42.
    [24]
    Frey N， Porter D. Cytokine release syndrome with chimeric antigen receptor T cell therapy［J］. Biol Blood Marrow Transplant， 2019， 25（4）： e123-e127.
    [25]
    Neelapu SS， Locke FL， Bartlett NL， et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma［J］. N Engl J Med， 2017， 377（26）： 2531-2544.
    [26]
    Ji TJ， Lang JY， Ning B， et al. Enhanced natural killer cell immunotherapy by rationally assembling fc fragments of antibodies onto tumor membranes［J］. Adv Mater， 2019， 31（6）： e1804395.
    [27]
    Chiu J， Ernst DM， Keating A. Acquired natural killer cell dysfunction in the tumor microenvironment of classic Hodgkin lymphoma［J］. Front Immunol， 2018， 9： 267.
    [28]
    Ibrahim EC， Guerra N， Lacombe MJ， et al. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma［J］. Cancer Res， 2001， 61（18）： 6838-6845.
    [29]
    Hu Y， Tian ZG， Zhang C. Chimeric antigen receptor （CAR）-transduced natural killer cells in tumor immunotherapy［J］. Acta Pharmacol Sin， 2018， 39（2）： 167-176.
    [30]
    Han JF， Chu JH， Keung Chan W， et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells［J］. Sci Rep， 2015， 5： 11483.
    [31]
    Burger MC， Zhang C， Harter PN， et al. CAR-engineered NK cells for the treatment of glioblastoma： turning innate effectors into precision tools for cancer immunotherapy［J］. Front Immunol， 2019， 10： 2683.
    [32]
    Li Y， Hermanson DL， Moriarity BS， et al. Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity［J］. Cell Stem Cell， 2018， 23（2）： 181-192.e5.
    [33]
    Liu E， Marin D， Banerjee P， et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors［J］. N Engl J Med， 2020， 382（6）： 545-553.
    [34]
    Hu Y， Tian ZG， Zhang C. Natural killer cell-based immunotherapy for cancer： advances and prospects［J］. Engineering， 2019， 5（1）： 106-114.
    [35]
    Song Q， Zhang CD， Wu XH. Therapeutic cancer vaccines： From initial findings to prospects［J］. Immunol Lett， 2018， 196： 11-21.
    [36]
    Bowen WS， Svrivastava AK， Batra L， et al. Current challenges for cancer vaccine adjuvant development［J］. Expert Rev Vaccines， 2018， 17（3）： 207-215.
    [37]
    van der Burg SH， Arens R， Ossendorp F， et al. Vaccines for established cancer： overcoming the challenges posed by immune evasion［J］. Nat Rev Cancer， 2016， 16（4）： 219-233.
    [38]
    Aldous AR， Dong JZ. Personalized neoantigen vaccines： a new approach to cancer immunotherapy［J］. Bioorg Med Chem， 2018， 26（10）： 2842-2849.
    [39]
    Chen FJ， Zou ZY， Du J， et al. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors［J］. J Clin Invest， 2019， 129（5）： 2056-2070.
    [40]
    Hilf N， Kuttruff-Coqui S， Frenzel K， et al. Actively personalized vaccination trial for newly diagnosed glioblastoma［J］. Nature， 2019， 565（7738）： 240-245.
    [41]
    Keskin DB， Anandappa AJ， Sun J， et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial［J］. Nature， 2019， 565（7738）： 234-239.
    [42]
    Zang R， Jiang T， Zeng TZ， et al. Advances of combined immunotherapy in tumor［J］. J China Pharm Univ （中国药科大学学报）， 2018， 49（4）： 383-391.
    [43]
    Sahin U， ?Türeci. Personalized vaccines for cancer immunotherapy［J］. Science， 2018， 359（6382）： 1355-1360.
    [44]
    Hennessy ML， Bommareddy PK， Boland G， et al. Oncolytic immunotherapy［J］. Surg Oncol Clin N Am， 2019， 28（3）： 419-430.
    [45]
    Bommareddy PK， Shettigar M， Kaufman HL. Integrating oncolytic viruses in combination cancer immunotherapy［J］. Nat Rev Immunol， 2018， 18（8）： 498-513.
    [46]
    Breitbach CJ， Bell JC， Hwang TH， et al. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec （JX-594）［J］. Oncolytic Virother， 2015， 4： 25-31.
    [47]
    Kaufman HL， Kohlhapp FJ， Zloza A. Oncolytic viruses： a new class of immunotherapy drugs［J］. Nat Rev Drug Discov， 2015， 14（9）： 642-662.
    [48]
    Rosewell Shaw A， Suzuki M. Oncolytic viruses partner with T-cell therapy for solid tumor treatment［J］. Front Immunol， 2018， 9： 2103.
    [49]
    Russell L， Peng KW， Russell SJ， et al. Oncolytic viruses： priming time for cancer immunotherapy［J］. BioDrugs， 2019， 33（5）： 485-501.
    [50]
    Tsun A， Miao XN， Wang CM， et al. Oncolytic immunotherapy for treatment of cancer［J］. Adv Exp Med Biol， 2016， 909： 241-283.
    [51]
    Yl?sm?ki E， Cerullo V. Design and application of oncolytic viruses for cancer immunotherapy［J］. Curr Opin Biotechnol， 2020， 65： 25-36.
    [52]
    Qin S， Xu LP， Yi M， et al. Novel immune checkpoint targets： moving beyond PD-1 and CTLA-4［J］. Mol Cancer， 2019， 18（1）： 155.
    [53]
    Xin X， Pei X， Yang X， et al. Rod-shaped active drug particles enable efficient and safe gene delivery［J］. Adv Sci （Weinh）， 2017， 4（11）： 1700324.
    [54]
    Xin XF， Teng C， Du XQ， et al. Drug-delivering-drug platform-mediated potent protein therapeutics via a non-endo-lysosomal route［J］. Theranostics， 2018， 8（13）： 3474-3489.
    [55]
    Xin XF， Du XQ， Xiao QQ， et al. Drug nanorod-mediated intracellular delivery of microRNA-101 for self-sensitization via autophagy inhibition［J］. Nano-Micro Lett， 2019， 11（1）： 1-16.
    [56]
    Ma LY， Dichwalkar T， Chang JYH， et al. Enhanced CAR-T cell activity against solid tumors by vaccine boosting through the chimeric receptor［J］. Science， 2019， 365（6449）： 162-168.
    • Related Articles

  • Related Articles

    [1]MU Yao, ZHAO Huimin, LIU Haochen, LIU Xiaoquan. Advances in drug development for Alzheimer’s disease[J]. Journal of China Pharmaceutical University, 2024, 55(6): 816-825. DOI: 10.11665/j.issn.1000-5048.2024010202
    [2]WANG Shihao, LIU Lifeng, DING Yang, LI Suxin. Research progress of pH-responsive drug delivery systems in cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2024, 55(4): 522-529. DOI: 10.11665/j.issn.1000-5048.2024011902
    [3]CUI Zhenzhen, ZHAO Yifan, SUN Yu, Meng Jiayi, KANG Di, HU Lihong. Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis[J]. Journal of China Pharmaceutical University, 2024, 55(1): 36-44. DOI: 10.11665/j.issn.1000-5048.2023112904
    [4]CHEN Feihong, ZHAO Deming, GOU Shaohua. Research progress on the antitumor effects of platinum-based chemo-immunotherapies[J]. Journal of China Pharmaceutical University, 2024, 55(1): 26-35. DOI: 10.11665/j.issn.1000-5048.2023120201
    [5]LIU Yanhong, CHEN Liqing, ZHANG Xintong, GAO Zhonghao, HUANG Wei. Research progress of tumor immunomodulation strategies based on nanodrug delivery system[J]. Journal of China Pharmaceutical University, 2023, 54(1): 5-14. DOI: 10.11665/j.issn.1000-5048.2023021501
    [6]ZHANG Yu, YAN Fang, XIAO Yibei. Development of VISTA in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 400-409. DOI: 10.11665/j.issn.1000-5048.20220403
    [7]YAO Zheng, LI Zihan, GAO Liming, HU Xing, CHEN Yan, PAN Wenqi, LI Qian. Advances of research on CAR-T cell immunotherapy for solid tumors[J]. Journal of China Pharmaceutical University, 2021, 52(4): 496-504. DOI: 10.11665/j.issn.1000-5048.20210413
    [8]ZHANG Jing. Analysis on research and development of global cardiovascular drugs in the past 6 years[J]. Journal of China Pharmaceutical University, 2018, 49(6): 760-765. DOI: 10.11665/j.issn.1000-5048.20180619
    [9]WANG Juan, LIAO Hong. Advances in drug research and development through directed differentiation of stem cells[J]. Journal of China Pharmaceutical University, 2011, 42(3): 193-197.
    [10]Application of pharmacometrics in drug development and therapeutic drug monitoring[J]. Journal of China Pharmaceutical University, 2010, 41(1): 91-96.

  • Cited by

    Periodical cited type(19)

    1. 吴娅芳，胡展驰，王毅，权春善. 细菌外膜囊泡在疫苗领域的应用研究进展. 工业微生物. 2024(01): 100-106 .
    2. 宁华汉，李芊芊，吴哲丹，李晓飞. 程序性死亡配体-1与OX40L在NK/T细胞淋巴瘤中的表达及临床意义. 锦州医科大学学报. 2024(02): 80-85 .
    3. 孙晶莹，李研，黄晓燕，靳占奎，徐翠香，常乐，王建华. 链霉亲和素-人粒细胞巨噬细胞集落刺激因子融合蛋白的制备与活性鉴定. 陕西医学杂志. 2023(01): 3-6+22 .
    4. 成晓霞，王子见，何凤琴，成瀛. 活性氧在红缘拟层孔菌杀伤白血病细胞中的作用研究. 西北大学学报(自然科学版). 2023(01): 68-76 .
    5. 孙彦顺，姜诗瑶，杨东，崔钰，刘青，于莉莉. 卡瑞利珠单抗注射液临床用药特征分析. 武警医学. 2023(04): 325-329 .
    6. 彭丞，陈嘉斌，柴可群，严楷蕾. 肠道菌群在肿瘤应用中的研究进展. 实用肿瘤杂志. 2023(03): 290-293 .
    7. 王欣欣，闫振宇，苏博. 基于TCGA数据库分析肌动蛋白结合蛋白1在头颈部鳞状细胞癌中的表达及对预后的影响. 中国卫生检验杂志. 2023(13): 1621-1624 .
    8. 白紫合，李娟，吕雅蕾. Her2低表达晚期乳腺癌药物治疗的研究进展. 河北医科大学学报. 2023(07): 860-865 .
    9. 孙彦顺，王陵，姜诗瑶，杨东，刘青，于莉莉. 基于真实世界的肿瘤免疫治疗药物PD-1/PD-L1抑制剂使用情况分析. 中国医科大学学报. 2023(09): 769-774 .
    10. 吴丛宇，周悦，上官璐茜，杨雅妮，王晶雅，余俊河，宫帅帅，寇俊萍. 大黄素的药理作用机制研究进展. 中国药科大学学报. 2023(05): 634-643 . 本站查看
    11. 丁子文，汪璐，任燕，郑岩，李渊，张婧妍，倪娜. 白介素15在肿瘤免疫治疗中的临床研究进展. 世界临床药物. 2022(01): 87-90+104 .
    12. 陈勇，彭思意，刘小保，李坤艳，魏涛，李旭英. 肿瘤专科医院Ⅰ期临床研究病房的建设与实践. 护理学报. 2022(05): 32-36 .
    13. 赖桂花，王菲，周芳，聂多锐，曹建雄. 差异视角下中西医治疗肿瘤的协同优势. 中医药临床杂志. 2022(04): 599-603 .
    14. 毛露珈，史恩宇，王瀚平，单天贺，王银松，王悦. 细菌外膜囊泡在抗肿瘤治疗方面的研究进展. 中国生物工程杂志. 2022(05): 100-105 .
    15. 张永健，李红专，史恒蔚，许伟，李彦强. 从虚痰瘀毒论治恶性骨肿瘤. 中医研究. 2022(07): 5-8 .
    16. 阮勤钊，李向敏，王涓，谢意珍，吴清平. 基于髓源性抑制细胞的食药用菌多糖抗肿瘤免疫作用机制. 微生物学报. 2022(08): 2969-2980 .
    17. 王昕，付洁，严颐丹，苏颖杰，寇焰宇，管丽，林厚文. 新型抗肿瘤药物研究进展与临床应用. 上海医药. 2022(S2): 9-21 .
    18. 孙偲，武彦昊，郭佳亿，白杨，郝慧芳. 外膜囊泡在肿瘤疫苗中的应用研究进展. 生命科学. 2022(11): 1431-1441 .
    19. 胡秦，杨怡姝，贾润清，盛望. 生物技术专业免疫学课程思政教学实践与探索. 中国教育技术装备. 2022(04): 78-80 .

    Other cited types(29)

Catalog

    Get Citation
    PDF
    XML
    Article views (1267) PDF downloads (1639) Cited by(48)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：303101

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return